Results 1 to 10 of about 81,192 (267)

Contribution of pannexin1 to experimental autoimmune encephalomyelitis. [PDF]

open access: yesPLoS ONE, 2013
Pannexin1 (Panx1) is a plasma membrane channel permeable to relatively large molecules, such as ATP. In the central nervous system (CNS) Panx1 is found in neurons and glia and in the immune system in macrophages and T-cells. We tested the hypothesis that
Sarah E Lutz   +10 more
doaj   +6 more sources

Amelioration of experimental autoimmune encephalomyelitis by anatabine. [PDF]

open access: yesPLoS ONE, 2013
Anatabine, a naturally occurring alkaloid, is becoming a commonly used human food supplement, taken for its claimed anti-inflammatory properties although this has not yet been reported in human clinical trials.
Daniel Paris   +7 more
doaj   +5 more sources

Peptide immunotherapy in experimental autoimmune encephalomyelitis [PDF]

open access: yesBiomedical Journal, 2015
We now have potent drugs available to treat the inflammatory component of multiple sclerosis (MS). However, not all patients respond, the drugs are not curative, and the associated risks to beneficial immune surveillance are considerable.
Stephen M Anderton
doaj   +4 more sources

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis [PDF]

open access: yes, 2013
PMCID ...
A Compston   +92 more
core   +16 more sources

Evaluation of methods of modeling and formation of experimental allergic encephalomyelitis [PDF]

open access: yesResearch Results in Pharmacology, 2022
Introduction: Experimental autoimmune (allergic) encephalomyelitis (EAE) induced by intradermal injection of homogenate of the brain, spinal cord and peripheral nerve with Freund’s stimulator, refers to a true autoimmune disease of the nervous system.
Oleksandr O. Nefodov   +5 more
doaj   +3 more sources

MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis

open access: yesNeural Regeneration Research, 2020
Multiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination.
Bridget Martinez, Philip V Peplow
doaj   +1 more source

Should mast cells be considered therapeutic targets in multiple sclerosis?

open access: yesNeural Regeneration Research, 2020
Mast cells are immune cells of the myeloid lineage that are found throughout the body, including the central nervous system. They perform many functions associated with innate and specific immunity, angiogenesis, and vascular homeostasis.
Karen Henriette Pinke   +3 more
doaj   +1 more source

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling

open access: yesCells, 2023
Our previous work demonstrated that vitamin D (VitD) reduces experimental autoimmune encephalomyelitis (EAE) disease severity in wild-type (WT) but not in T cell-specific glucocorticoid (GC) receptor (GR)-deficient (GRlck) mice.
Maud Bagnoud   +7 more
doaj   +1 more source

Emerging immunopharmacological targets in multiple sclerosis. [PDF]

open access: yes, 2015
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami   +182 more
core   +2 more sources

Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]

open access: yes, 2016
Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy